Thrivent Financial for Lutherans boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 140.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,159,356 shares of the biopharmaceutical company's stock after buying an additional 1,262,193 shares during the quarter. Thrivent Financial for Lutherans owned 0.17% of Gilead Sciences worth $148,153,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Manning & Napier Advisors LLC acquired a new position in Gilead Sciences in the 2nd quarter worth $25,328,000. Eagle Asset Management Inc. raised its stake in shares of Gilead Sciences by 23.6% in the 4th quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company's stock valued at $25,724,000 after purchasing an additional 60,697 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at about $462,000. Brookstone Capital Management raised its stake in shares of Gilead Sciences by 751.1% in the 1st quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company's stock valued at $9,322,000 after purchasing an additional 112,305 shares in the last quarter. Finally, Comerica Bank raised its stake in shares of Gilead Sciences by 10.7% in the 4th quarter. Comerica Bank now owns 329,990 shares of the biopharmaceutical company's stock valued at $26,733,000 after purchasing an additional 31,849 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Insider Buying and Selling at Gilead Sciences
In other news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now owns 114,979 shares of the company's stock, valued at approximately $8,506,146.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Johanna Mercier sold 5,490 shares of the firm's stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company's stock, valued at approximately $8,506,146.42. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The disclosure for this sale can be found here. In the last three months, insiders sold 36,847 shares of company stock valued at $3,002,940. 0.16% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada upped their target price on shares of Gilead Sciences from $72.00 to $74.00 and gave the company a "sector perform" rating in a research note on Wednesday, September 4th. BMO Capital Markets upped their target price on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an "outperform" rating in a research note on Friday, August 9th. Robert W. Baird restated a "neutral" rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Thursday, June 20th. Cantor Fitzgerald restated a "neutral" rating and issued a $70.00 target price on shares of Gilead Sciences in a research note on Monday, September 16th. Finally, Evercore ISI upgraded shares of Gilead Sciences to a "strong-buy" rating in a research note on Friday, August 9th. Twelve equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $82.06.
Read Our Latest Stock Report on GILD
Gilead Sciences Price Performance
Shares of NASDAQ:GILD traded up $0.04 during trading on Friday, reaching $83.94. The company had a trading volume of 24,925,966 shares, compared to its average volume of 7,289,311. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The firm has a market capitalization of $104.58 billion, a PE ratio of 233.17, a price-to-earnings-growth ratio of 2.80 and a beta of 0.18. The firm's fifty day moving average is $76.95 and its 200 day moving average is $71.25.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. On average, equities analysts forecast that Gilead Sciences, Inc. will post 3.78 EPS for the current year.
Gilead Sciences Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.67%. The ex-dividend date is Friday, September 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 855.56%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
